NZ576782A - Pyrido[2,3-b]indol derivatives as kinase inhibitors - Google Patents
Pyrido[2,3-b]indol derivatives as kinase inhibitorsInfo
- Publication number
- NZ576782A NZ576782A NZ576782A NZ57678207A NZ576782A NZ 576782 A NZ576782 A NZ 576782A NZ 576782 A NZ576782 A NZ 576782A NZ 57678207 A NZ57678207 A NZ 57678207A NZ 576782 A NZ576782 A NZ 576782A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- disease
- indol
- pyrido
- yloxy
- Prior art date
Links
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical class C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- CIXLEDXEBCVQQS-UHFFFAOYSA-N 2-[3-[[5-(3-cyclopropylsulfonylphenyl)-3-methyl-9h-pyrido[2,3-b]indol-8-yl]oxy]propyl-ethylamino]ethyl dihydrogen phosphate Chemical compound C1=2C3=CC(C)=CN=C3NC=2C(OCCCN(CC)CCOP(O)(O)=O)=CC=C1C(C=1)=CC=CC=1S(=O)(=O)C1CC1 CIXLEDXEBCVQQS-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- QJQQQWWHMWFOIN-UHFFFAOYSA-N 2-[3-[[5-(3-ethylsulfonylphenyl)-3-methyl-9h-pyrido[2,3-b]indol-8-yl]oxy]propyl-methylamino]ethanol Chemical compound CCS(=O)(=O)C1=CC=CC(C=2C=3C4=CC(C)=CN=C4NC=3C(OCCCN(C)CCO)=CC=2)=C1 QJQQQWWHMWFOIN-UHFFFAOYSA-N 0.000 abstract 1
- PCZNILTUYMGMLK-UHFFFAOYSA-N 2-[3-[[5-(3-ethylsulfonylphenyl)-3-methyl-9h-pyrido[2,3-b]indol-8-yl]oxy]propyl-methylamino]ethyl dihydrogen phosphate Chemical compound CCS(=O)(=O)C1=CC=CC(C=2C=3C4=CC(C)=CN=C4NC=3C(OCCCN(C)CCOP(O)(O)=O)=CC=2)=C1 PCZNILTUYMGMLK-UHFFFAOYSA-N 0.000 abstract 1
- KGPUSRIQFMGJKH-UHFFFAOYSA-N 2-[3-[[5-[3-(cyclopropylcarbamoyl)phenyl]-3-methyl-9h-pyrido[2,3-b]indol-8-yl]oxy]propyl-ethylamino]ethyl dihydrogen phosphate Chemical compound C1=2C3=CC(C)=CN=C3NC=2C(OCCCN(CC)CCOP(O)(O)=O)=CC=C1C(C=1)=CC=CC=1C(=O)NC1CC1 KGPUSRIQFMGJKH-UHFFFAOYSA-N 0.000 abstract 1
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003571 Astrocytoma Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000007766 Kaposi sarcoma Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000014060 Niemann-Pick disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 230000002254 contraceptive effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 208000024963 hair loss Diseases 0.000 abstract 1
- 230000003676 hair loss Effects 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 206010041823 squamous cell carcinoma Diseases 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed are pyrido[2,3-b]indol derivatives which are useful as kinase inhibitors, and are as represented by the general formula (I), wherein the substituents are as defined herein. Representative compounds include 2-((3-(5-(3-(cyclopropylcarbamoyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate; 2-((3-(5-(3-(ethylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(methyl)amino)ethanol, 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9Hpyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate, 2-((3-(5-(3-(ethylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(methyl)amino)ethyl dihydrogen phosphate and 2-((3-(5-(3-(cyclopropylsulfonyl)phenyl)-3-methyl-9H-pyrido[2,3-b]indol-8-yloxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate. Further disclosed is a pharmaceutical composition which comprises as an active ingredient, a compound as defined above, together with a pharmaceutically acceptable carrier, for the treatment of conditions such as cancer, squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, non small-cell lung cancer, bladder cancer, head and neck cancer, melanoma, etc., inflammation, inflammatory bowel disease, psoriasis, transplant rejection, amyotrophic lateral sclerosis, corticobasal degeneration, Down's syndrome, Huntington's Disease, Parkinson's Disease, postencephelatic parkinsonism, progressive supranuclear palsy, Pick's Disease, Niemann-Pick's Disease, stroke, head trauma and other chronic neurodegenerative diseases, Bipolar Disease, affective disorders, depression, schizophrenia, cognitive disorders, dementia related diseases, Alzheimer's Disease, hair loss and as a contraceptive medication.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/539,857 US8119655B2 (en) | 2005-10-07 | 2006-10-09 | Kinase inhibitors |
| US3966706A | 2006-10-10 | 2006-10-10 | |
| US91262907P | 2007-04-18 | 2007-04-18 | |
| PCT/US2007/080714 WO2008054956A2 (en) | 2006-10-09 | 2007-10-08 | Kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ576782A true NZ576782A (en) | 2012-08-31 |
Family
ID=46755235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ576782A NZ576782A (en) | 2006-10-09 | 2007-10-08 | Pyrido[2,3-b]indol derivatives as kinase inhibitors |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ576782A (en) |
-
2007
- 2007-10-08 NZ NZ576782A patent/NZ576782A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY166866A (en) | Heterocyclic derivative and pharmaceutical drug | |
| PH12018500940A1 (en) | N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases | |
| MX347706B (en) | Triazole derivatives and their use for neurological disorders. | |
| PH12014502886A1 (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| GEP20125405B (en) | Amino-heterocyclic compounds | |
| GEP20156348B (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| WO2010043953A3 (en) | Novel bridged cyclic compounds as histone deacetylase inhibitors | |
| PH12015501878A1 (en) | Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative | |
| NZ630721A (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use | |
| MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| MX2009010951A (en) | 3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c. | |
| WO2011156698A3 (en) | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | |
| NZ741907A (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| WO2006001511A8 (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as crf antagonists | |
| MY172110A (en) | Substituted n-(1h-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type iii receptor tyrosine kinase inhibitors | |
| NZ597122A (en) | Bridged spiro [2.4] heptane derivatives as alx receptor and/or fprl2 agonists | |
| PE20141167A1 (en) | PYRIDOPYRAZINES SUBSTITUTED AS NOVEL PTK INHIBITORS | |
| WO2006065686A3 (en) | Spiro derivatives as lipoxygenase inhibitors | |
| WO2014093583A3 (en) | Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof | |
| PH12016501864A1 (en) | Chromene and 1, 1a, 2, 7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators | |
| NZ603108A (en) | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators | |
| NZ705144A (en) | Ethynyl derivatives as modulators of mglur5 receptor activity | |
| Bencsik et al. | Discovery of dihydrothieno-and dihydrofuropyrimidines as potent pan Akt inhibitors | |
| NZ576782A (en) | Pyrido[2,3-b]indol derivatives as kinase inhibitors | |
| PH12012502293A1 (en) | NOVEL ANTIFUNGAL 5,6-DIHYDRO-4-[(DIFLUOROETHYL)PHENYL]-4H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE AND 4-(DIFLUOROETHYL)PHENYL-6H-PYRROLO[1,2-a][1,4]BENZODIAZEPINE DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JP Free format text: OLD OWNER(S): TAKEDA SAN DIEGO, INC. |
|
| LAPS | Patent lapsed |